Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure ...

30,134 people played the daily Crossword recently. Can you solve it faster than others?30,134 people played the daily Crossword recently. Can you solve it faster than others? Investing $10,000 in ...